MedPath

Y-mAbs Therapeutics

Y-mAbs Therapeutics logo
๐Ÿ‡บ๐Ÿ‡ธUnited States
Ownership
Public
Established
2015-04-01
Employees
100
Market Cap
$676.1M
Website
http://www.ymabs.com
Introduction

Y-mAbs Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer. Its services include discovery, protein engineering, clinical and regulatory. Y-mAbs Therapeutics was founded by Thomas Gad in April 2015 and is headquartered in New York, NY.

Phase 1, Open-label, Dose-escalation Trial with CD38-SADA:177 Lu-DOTA Drug Complex in Subjects with Relapsed or Refractory Non-Hodgkin Lymphoma

Phase 1
Recruiting
Conditions
Non-hodgkin Lymphoma
First Posted Date
2023-08-16
Last Posted Date
2025-03-25
Lead Sponsor
Y-mAbs Therapeutics
Target Recruit Count
30
Registration Number
NCT05994157
Locations
๐Ÿ‡บ๐Ÿ‡ธ

HonorHealth, Scottsdale, Arizona, United States

๐Ÿ‡บ๐Ÿ‡ธ

City of Hope, Duarte, California, United States

๐Ÿ‡บ๐Ÿ‡ธ

Corewell Health-BAMF Health, Grand Rapids, Michigan, United States

and more 3 locations

GD2-SADA:177Lu-DOTA Complex in Patients With Solid Tumors Known to Express GD2

Phase 1
Recruiting
Conditions
SCLC
Malignant Melanoma
Sarcoma
High Risk Neuroblastoma
First Posted Date
2021-11-23
Last Posted Date
2024-10-02
Lead Sponsor
Y-mAbs Therapeutics
Target Recruit Count
60
Registration Number
NCT05130255
Locations
๐Ÿ‡บ๐Ÿ‡ธ

Corewell Health-BAMF Health, Grand Rapids, Michigan, United States

๐Ÿ‡บ๐Ÿ‡ธ

Memorial Sloan- Kettering Cancer Center, New York, New York, United States

๐Ÿ‡บ๐Ÿ‡ธ

HonorHealth, Scottsdale, Arizona, United States

and more 5 locations

A Phase 1 Trial of CD33xCD3 BsAb in Pediatric Patients With Relapsed or Refractory Acute Myeloid Leukemia

Phase 1
Terminated
Conditions
AML, Childhood
Interventions
Drug: CD33*CD3 BsAb
First Posted Date
2021-10-14
Last Posted Date
2023-05-30
Lead Sponsor
Y-mAbs Therapeutics
Target Recruit Count
3
Registration Number
NCT05077423
Locations
๐Ÿ‡บ๐Ÿ‡ธ

Washington University School of Medicine, Saint Louis, Missouri, United States

๐Ÿ‡บ๐Ÿ‡ธ

UPMC Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania, United States

๐Ÿ‡บ๐Ÿ‡ธ

University of Minnesota/Masonic Cancer Center, Minneapolis, Minnesota, United States

and more 10 locations

131I-omburtamab Delivered by Convection-Enhanced Delivery in Patients With Diffuse Intrinsic Pontine Glioma

Phase 1
Withdrawn
Conditions
DIPG
Interventions
Device: Convention Enhanced Delivery
First Posted Date
2021-10-01
Last Posted Date
2023-06-26
Lead Sponsor
Y-mAbs Therapeutics
Registration Number
NCT05063357

Naxitamab and Granulocyte-Macrophage Colony Stimulating Factor (GMCSF) and Isotretinoin for Consolidation of Patients With High-Risk Neuroblastoma in First Remission.

Phase 2
Withdrawn
Conditions
Neuroblastoma
Interventions
First Posted Date
2021-06-01
Last Posted Date
2022-09-01
Lead Sponsor
Y-mAbs Therapeutics
Registration Number
NCT04909515
Locations
๐Ÿ‡ท๐Ÿ‡บ

National Medical Research Center Pediatric Hematology, Oncology and Immunology n.a Dmitry Rogachev, Moscow, Russian Federation

๐Ÿ‡ธ๐Ÿ‡ฌ

ICON Cancer Centre Novena, Singapore, Singapore

๐Ÿ‡ท๐Ÿ‡บ

Research Institute of Pediatric Oncology ad Hematology of N.N. Blokhin National Medical Research Center of Oncology, Moscow, Russian Federation

and more 6 locations

Safety and Clinical Activity of Nivatrotamab in Relapsed/Recurrent Metastatic Small-cell Lung Cancer

Phase 1
Terminated
Conditions
SCLC
Interventions
First Posted Date
2021-02-11
Last Posted Date
2023-08-14
Lead Sponsor
Y-mAbs Therapeutics
Target Recruit Count
3
Registration Number
NCT04750239
Locations
๐Ÿ‡บ๐Ÿ‡ธ

Washington University School of Medicine, Saint Louis, Missouri, United States

๐Ÿ‡บ๐Ÿ‡ธ

Moffitt Cancer Center, Tampa, Florida, United States

๐Ÿ‡บ๐Ÿ‡ธ

Emory University, Atlanta, Georgia, United States

and more 4 locations

Naxitamab and GM-CSF in Combination With IT in Patients With High-Risk Neuroblastoma

Phase 2
Terminated
Conditions
Neuroblastoma Recurrent
Interventions
First Posted Date
2020-09-23
Last Posted Date
2024-03-18
Lead Sponsor
Y-mAbs Therapeutics
Target Recruit Count
2
Registration Number
NCT04560166
Locations
๐Ÿ‡ฐ๐Ÿ‡ท

Asan Medical Center Children's Hospital, Seoul, Korea, Republic of

๐Ÿ‡ฐ๐Ÿ‡ท

Seoul National University Hospital, Seoul, Korea, Republic of

๐Ÿ‡ญ๐Ÿ‡ฐ

Hong Kong Children's Hospital, Hong Kong, Hong Kong

177Lu-DTPA-Omburtamab Radioimmunotherapy for Leptomeningeal Metastasis From Solid Tumors (Breast, NSCLC, Malignant Melanoma)

Phase 1
Withdrawn
Conditions
Solid Tumor, Adult
Leptomeningeal Metastasis
Interventions
Biological: radiolabeled DPTA-omburtamab
First Posted Date
2020-03-19
Last Posted Date
2022-07-15
Lead Sponsor
Y-mAbs Therapeutics
Registration Number
NCT04315246
Locations
๐Ÿ‡บ๐Ÿ‡ธ

Memorial Sloan Kettering Cancer Center, New York, New York, United States

๐Ÿ‡บ๐Ÿ‡ธ

Duke Cancer Center, Durham, North Carolina, United States

๐Ÿ‡ฌ๐Ÿ‡ง

The Christie Hospital NHS Foundation Trust, Manchester, United Kingdom

and more 5 locations

177Lu-DTPA-Omburtamab Radioimmunotherapy for Recurrent or Refractory Medulloblastoma

Phase 1
Terminated
Conditions
Medulloblastoma, Childhood
Interventions
First Posted Date
2019-11-19
Last Posted Date
2023-10-06
Lead Sponsor
Y-mAbs Therapeutics
Target Recruit Count
2
Registration Number
NCT04167618
Locations
๐Ÿ‡บ๐Ÿ‡ธ

Mayo Clinic, Rochester, Minnesota, United States

๐Ÿ‡บ๐Ÿ‡ธ

Doernbecher Children's Hospital, Portland, Oregon, United States

๐Ÿ‡บ๐Ÿ‡ธ

Memorial Sloan Kettering Cancer Center, New York, New York, United States

and more 7 locations

Study of the Safety and Efficacy of Humanized 3F8 Bispecific Antibody (Hu3F8-BsAb) in Patients With Relapsed/Refractory Neuroblastoma, Osteosarcoma and Other Solid Tumor Cancers

Phase 1
Terminated
Conditions
Osteosarcoma
Neuroblastoma
Other Solid Tumor Cancers
Interventions
Biological: Humanized 3F8 Bispecific Antibody
Other: Blood draw
First Posted Date
2019-03-01
Last Posted Date
2023-09-13
Lead Sponsor
Y-mAbs Therapeutics
Target Recruit Count
12
Registration Number
NCT03860207
Locations
๐Ÿ‡บ๐Ÿ‡ธ

Memorial Sloan Kettering Cancer Center, New York, New York, United States

ยฉ Copyright 2025. All Rights Reserved by MedPath